Gilead Sciences

AIDS activists criticized the Biden administration's R&D agreement with Gilead Sciences over HIV prevention drug patents, arguing it missed an opportunity to expand access to such tools. The deal resolved a Trump-era lawsuit alleging Gilead infringed CDC-funded research used to develop Truvada and Descovy, with the administration accusing Gilead of ignoring CDC contributions and refusing licensing agreements.

Researchers initiated a study on two potential Ebola treatments, remdesivir and MBP134, in Congo to address the worsening Bundibugyo virus outbreak, which has infected over 1,400 people and caused 438 deaths. The trial, led by the WHO and partners, aims to determine if the drugs improve survival rates and will enroll participants in eastern Congo, with possible expansion to safer regions.

Researchers in Congo began testing two potential Ebola treatments, remdesivir and MBP134, to address the worsening Bundibugyo virus outbreak, which has infected over 1,400 people and caused 438 deaths. The World Health Organization (WHO) is leading the trial, which aims to determine if these drugs improve survival rates in combination with standard care. The study involves collaboration with Congo’s INRB, Oxford University, and other international health groups.

Researchers in Congo have initiated a study to test two potential Ebola treatments, remdesivir and MBP134, amid a worsening outbreak caused by the Bundibugyo virus. The World Health Organization reported over 1,400 cases and 438 deaths, with the trial aiming to determine if the drugs improve survival rates. The study, conducted in collaboration with multiple international institutions, faces challenges due to violence in the region.

GSK acquired Nuvalent, a cancer drug developer, in a $10.6 billion deal to expand its oncology portfolio, while Merck and Gilead Sciences reported success in final-stage trials for a once-weekly HIV pill combining their experimental drugs. The GSK acquisition highlights ongoing biopharma industry consolidation as companies bolster pipelines amid generic competition.

An FDA advisory panel recommended updating fall 2023 Covid vaccines to target the XFG variant. Pfizer and China’s Innovent Biologics announced a $10.5 billion global collaboration to develop 12 early-stage cancer drugs. The WHO fast-tracked three existing drugs for testing against the Bundibugyo Ebola outbreak in the Democratic Republic of the Congo.